Goldman Sachs’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.6M | Buy |
|
|||||
|
2025
Q1 | $9.03M | Sell |
|
|||||
|
2024
Q4 | $9.35M | Buy |
|
|||||
|
2024
Q3 | $4M | Sell |
|
|||||
|
2024
Q2 | $3.75M | Sell |
|
|||||
|
2024
Q1 | $4.73M | Buy |
|
|||||
|
2023
Q4 | $773K | Sell |
|
|||||
|
2023
Q3 | $905K | Buy |
|
|||||
|
2023
Q2 | $825K | Sell |
|
|||||
|
2023
Q1 | $1.28M | Buy |
|
|||||
|
2022
Q4 | $963K | Buy |
|
|||||
|
2022
Q3 | $526K | Sell |
|
|||||
|
2022
Q2 | $523K | Buy |
|
|||||
|
2022
Q1 | $357K | Buy |
|
|||||
|
2021
Q4 | $521K | Buy |
|
|||||
|
2021
Q3 | $543K | Buy |
|
|||||
|
2021
Q1 | – | Sell |
|
|||||
|
2020
Q4 | $4.07M | Buy |
|